Purchase Order 75F40123P00138
Award Date 8/1/23
Potential Completion Date 7/31/24
Potential Value $21K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Rockville, MD 20850, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $16,514 purchase order to Arraystar Inc. to provide exosome miRNA profiling and sequencing services. The firm fixed price contract has a period of performance from September 19, 2023 through April 25, 2024 and will be performed in Silver Spring, Maryland. Arraystar will deliver the requested exosome profiling and sequencing services to support HHS FDA programs. No subcontractors or set aside designations...
- This is a $3,654.00 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services (HHS), to Arraystar Inc. for "OTHER FUNCTIONS MICROARRAY SERVICE". Arraystar Inc. is a for-profit company that specializes in innovative tools and sample to data services for non-coding RNA research, including long non-coding RNAs (LncRNAs), microRNAs, circular RNAs, and transfer RNAs. This...
- The Food and Drug Administration awarded a purchase order to Seqmatic, LLC for next-generation sequencing RNA reagents and testing services, valued at $99,900.00, on September 4, 2025. Seqmatic is a minority-owned, Asian-Pacific American-owned small business. Work will be performed in Silver Spring, Maryland, and completion is due March 6, 2027. The order calls for bulk RNA transcriptomics analysis on primary human hepatocytes to assess drug-associated adverse liver events, including 800 RNA...
- The Food and Drug Administration (FDA) awarded a $49,987.65 firm fixed price purchase order to Twinstrand Biosciences Inc. on June 27, 2024, for the Twinstrand Duplex Sequencing Mutagenesis Kit. The contract, with performance in Seattle, Washington, has an ultimate completion date of September 25, 2024, and was not issued under any set-aside designation. Twinstrand Biosciences Inc., a specialized genomic research company registered in the System for Award Management since 2016, develops advanced...
- The Food and Drug Administration awarded a firm fixed-price purchase order valued at $52,162.50 to Firalis for the provision of microRNA whole transcriptome assay services on human plasma samples. The contract, awarded on July 26, 2022, with a completion date of December 30, 2022, was executed without a set-aside designation. Performance of the work is scheduled to take place in Hungary. This procurement supports the FDA's research initiatives in biomarker analysis and cardiovascular...
- <p>The Food and Drug Administration issued a purchase order to Psomagen Inc. for whole genome sequencing services on the Illumina NovaSeq X platform, valued at $19,380, awarded September 17, 2024, under a total small business set-aside. Performance concludes September 19, 2025, at the awardee's facility in Rockville, Maryland. The order is firm fixed price.</p>
- The Food and Drug Administration awarded a $22.9K firm fixed-price purchase order to Pacific Biosciences of California, Inc., a Menlo Park-based biotechnology manufacturer specializing in advanced DNA and RNA sequencing technologies. The award, designated as a total small business set-aside, was executed on July 27, 2021, for SMRT cell 8M trays and Sequel II sequencing kits—consumable products essential for next-generation sequencing operations. The procurement was completed ahead of the October...
- The Department of Health and Human Services Food and Drug Administration awarded a $406,184 firm fixed price purchase order contract to Pacific Biosciences of California, Inc. for the provision of DNA sequencer and cluster generator hardware and software, as well as four annual preventative maintenance agreements to be exercised annually. The place of performance will be Laurel, Maryland and the period of performance is from September 26, 2023 through October 26, 2028. The contract was set aside...
- The Department of Health and Human Services Food and Drug Administration awarded a $136,975.00 firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents. The contract is for MiSeq sequencing service agreements covering four instruments, with a performance period ending on March 8, 2023. Illumina has previously received prime federal awards from agencies like the National Institutes of Health and Department of Veterans...
- This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA) to LC Sciences, a minority-owned, woman-owned, and Asian-Pacific American-owned business that manufactures goods and provides services for genomics and proteomics research. The $20,805 contract is for the delivery of "Mouse MicroRNA Microarray" services, which includes library preparation, sequencing of various types of RNA samples, and sequencing analysis. The contract has no set-aside...